Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Science to Business Program

University of Toronto

$60,000.00

Pre-clinical and clinical studies of novel biologics for the treatment of cancer. (2015 S2B CIHR to Rotman Business School)

EF 2014-15

Résumé
2015 S2B CIHR to Rotman Over the last two decades, more drugs than ever before have passed successfully through clinical trials and have been approved to treat cancer patients. However, despite these advances, many patients still die shortly after diagnosis due to a lack of treatment options or because some patients do not respond to currently available therapies. A major goal of the Campbell Family Institute for Cancer Research/Princess Margaret Cancer Center in Toronto is to discover new drug targets and develop therapies against these targets that can be used to treat cancer patients in the clinic. Under the leadership of Dr. Tak Mak, our team has taken concrete steps to achieving this goal by developing a specific inhibitor of PLK4, an enzyme that is essential for cancer cell growth in patients. We showed that this inhibitor is effective in killing human cancer cells in pre-clinical experiments and have recently received approval from Health Canada and the FDA to test this novel drug in cancer patients in Canada and the USA. In addition to our ongoing program of discovery and development of new chemical inhibitors, we are also developing antibodies that can serve as therapies for cancer patients. Our target discovery team has tested hundreds of cell surface proteins to determine whether they are involved in tumour growth and metastasis. To date, we have discovered 8 proteins that act in this way in mouse tumor models. We are currently developing antibodies against these proteins in order to block human tumour cell growth. We plan to test these potential new therapies in our laboratory using tumour tissues that have been generously donated by cancer patients receiving treatment at Princess Margaret Cancer Center. We believe that our work will shed light on the important fundamental processes driving tumour growth and metastasis. We are confident that we can exploit this knowledge to produce new treatment options for cancer patients in Canada and around the world.
Programme
Science to Business Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
325294
Name
Blaser Heiko M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Science to Business
Projecttitle
Pre-clinical and clinical studies of novel biologics for the treatment of cancer. (2015 S2B CIHR to Rotman Business School)
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
Science to Business Program
Keyworddelim
Biologics; Cancer; Monoclonal Antibodies; Oncology; Patient Derived Xenograft; Pre-Clinical; Therapeutics
Abstract
2015 S2B CIHR to Rotman Over the last two decades, more drugs than ever before have passed successfully through clinical trials and have been approved to treat cancer patients. However, despite these advances, many patients still die shortly after diagnosis due to a lack of treatment options or because some patients do not respond to currently available therapies. A major goal of the Campbell Family Institute for Cancer Research/Princess Margaret Cancer Center in Toronto is to discover new drug targets and develop therapies against these targets that can be used to treat cancer patients in the clinic. Under the leadership of Dr. Tak Mak, our team has taken concrete steps to achieving this goal by developing a specific inhibitor of PLK4, an enzyme that is essential for cancer cell growth in patients. We showed that this inhibitor is effective in killing human cancer cells in pre-clinical experiments and have recently received approval from Health Canada and the FDA to test this novel drug in cancer patients in Canada and the USA. In addition to our ongoing program of discovery and development of new chemical inhibitors, we are also developing antibodies that can serve as therapies for cancer patients. Our target discovery team has tested hundreds of cell surface proteins to determine whether they are involved in tumour growth and metastasis. To date, we have discovered 8 proteins that act in this way in mouse tumor models. We are currently developing antibodies against these proteins in order to block human tumour cell growth. We plan to test these potential new therapies in our laboratory using tumour tissues that have been generously donated by cancer patients receiving treatment at Princess Margaret Cancer Center. We believe that our work will shed light on the important fundamental processes driving tumour growth and metastasis. We are confident that we can exploit this knowledge to produce new treatment options for cancer patients in Canada and around the world.
Competitiondate
201502
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Blaser, Heiko M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $60,000~ $0~